A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Labrys Biologics; Teva Pharmaceutical Industries
  • Most Recent Events

    • 11 Jun 2017 Results of post-hoc analysis assessing efficacy of two doses of subcutaneous fremanezumab, presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 30 Sep 2015 According to a Teva Pharmaceuticals media release, data from this study were published in The Lancet Neurology.
    • 30 Sep 2015 Results published in a Teva Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top